Dr. Valentina Emmanuele

Dr. Chiriboga is Professor of Neurology and Pediatrics at CUIMC and former Interim Director of the Division of Child Neurology, Departments of Neurology and Pediatrics, Vagelos College of Physicians and Surgeons. She is also former Chief of Pediatric Neurology at Columbia University's affiliate hospital, Harlem Hospital Center.Dr. Chiriboga was born in Peru and educated in Argentina, where she graduated with Honors from the Faculty of Medicine at the National University of Buenos Aires in 1982. Dr. Chiriboga completed training in pediatrics at St. Luke's-Roosevelt Hospital in 1985. After completing her training in child neurology in 1988 at the Neurological Institute and Babies Hospital of Columbia-Presbyterian Medical Center, Dr. Chiriboga joined the Division of Child Neurology at NewYork-Presbyterian/Columbia University Irving Medical Center. Subsequently, she completed a Neuroepidemiology fellowship at the Gertrude H. Sergievsky Center and received a Master in Public Health from the Mailman School of Public Health, Columbia University. Dr. Chiriboga serves/has served on committees of the NIH, CNS, and ABPN. She is a diplomate of the ABPN in Child Neurology.Dr. Chiriboga's current research focuses on Spinal Muscular Atrophy (SMA) clinical trials. Past areas of research, including NIH funding, has focused on congenital infections and neurodevelopmental disorders, including cerebral palsy and effects of perinatal exposures. Her clinical practice focuses on neuromuscular disorders as well as developmental, neurobehavioral neurology, and migraine, and on the treatment of spasticity. Dr. Chiriboga is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Spinal Muscular Atrophy Type 2, and Spinal Muscular Atrophy Type 1. Dr. Chiriboga is board certified in Neurology With Special Qualification In Child Neurology and Child Neurology. Dr. Chiriboga is currently accepting new patients.

Solomon L. Moshé, MD, is Vice Chair of Neurology, Director of the Isabelle Rapin Child Neurology Division and Director of Clinical Neurophysiology at Montefiore. He is also the Charles Frost Chair in Neurosurgery and Neurology, Vice Chair, Saul R. Korey Department of Neurology, and Professor of Neurology, Neuroscience and Pediatrics at the Albert Einstein College of Medicine (Einstein). Dr. Moshé’s clinical focus is on epilepsy and electroencephalography with special emphasis on age-related influences on the expression, control and consequences of seizures. Dr. Moshe is highly rated in 13 conditions, according to our data. His clinical expertise encompasses West Syndrome, Spasmus Nutans, Epilepsy, and Seizures. Dr. Moshe is currently accepting new patients.

Matthew Harms, MD is an Associate Professor of Neurology. Dr. Harms received his A.B. in Biology summa cum laude from Harvard University in 1997, and his medical doctorate from the University of California San Francisco in 2003. He remained at San Francisco for neurology residency and served as Chief Resident in his final year. Dr. Harms completed neuromuscular medicine and clinical neurophysiology fellowships under the mentorship of Dr. Alan Pestronk at Washington University in St. Louis. His clinical training in neuromuscular diseases led him into the laboratory of Dr. Robert Baloh, where his post-doctoral research identified the genes responsible for two orphan human diseases- dominant spinal muscular atrophy with lower extremity predominance and limb-girdle muscular dystrophy type 1D.Dr. Harms joined the neuromuscular medicine faculty at Washington University in 2009 with board certifications in neurology, clinical neurophysiology, and neuromuscular medicine. In 2011, Dr. Harms assumed leadership of the Washington University Neuromuscular Genetics Project and established his research laboratory to continue harnessing emerging genetic technologies to understand the causes of inherited neuromuscular diseases. The lab focuses on diseases of the motor neuron, including amyotrophic lateral sclerosis, spinal muscular atrophy, and the hereditary motor neuropathies, and where his efforts have helped identify more than 5 novel disease genes. Here at Columbia, he will continue these efforts, directing an international multi-site effort using whole genome and transcriptome sequencing to bring precision medicine to amyotrophic lateral sclerosis. His laboratory efforts will occur in both the Motor Neuron Center and the Institute for Genomic Medicine. Dr. Harms is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), and Spinal Muscular Atrophy Type 3. Dr. Harms is board certified in Neurology, Clinical Neurophysiology, and Neuromuscular Medicine. Dr. Harms is currently accepting new patients.